<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573400</url>
  </required_header>
  <id_info>
    <org_study_id>IBD and neuropsychiatry</org_study_id>
    <nct_id>NCT04573400</nct_id>
  </id_info>
  <brief_title>Prevalence of Neuropsychiatric Manifestations in IBD Patients in Upper Egypt</brief_title>
  <official_title>Prevalence of Neuropsychiatric Manifestations in IBD Patients in Upper Egypt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Estimation of neuropsychiatric symptoms prevalence in IBD patients and their impact on&#xD;
      quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Crohn's disease (CD) and ulcerative colitis (UC) are the two main types of idiopathic&#xD;
      inflammatory bowel disease (IBD), clearly distinct pathophysiological entities. UC, the most&#xD;
      common form of IBD worldwide, is a disease of the colonic mucosa only; it is less prone to&#xD;
      complications. In contrast, CD is a transmural disease of the gastrointestinal mucosa which&#xD;
      can affect the entire gastrointestinal tract . CD and UC should be considered systemic&#xD;
      diseases since they are associated with clinical manifestations involving organs outside the&#xD;
      alimentary tract. Extraintestinal manifestations involve several organs, and either precede&#xD;
      the onset of intestinal manifestations or appear and evolve in parallel with them .&#xD;
      Neurologic involvement associated with IBD is frequently underreported. Nevertheless, it is&#xD;
      important to quantify the morbidity burden of clinically significant neurologic complications&#xD;
      in IBD because early recognition and treatment of neurologic diseases are crucial for&#xD;
      preventing major morbidity . Neurologic involvement in IBD as a subgroup of the EIMs may&#xD;
      precede the appearance of digestive symptoms or develop after diagnosis of IBD. In addition,&#xD;
      neurological symptoms may exacerbate during flare-ups of IBD or evolve independently from&#xD;
      intestinal manifestations without responding to treatment provided for the underlying bowel&#xD;
      disease.Within (IBD) literature, anxiety and depression symptoms are commonly identified to&#xD;
      be associated with increased disease activity and reduced quality of life. Research also&#xD;
      indicates that ongoing psychological distress can exacerbate disease activity,] and increase&#xD;
      the risk of flare-ups and health care costs. Given this, screening and targeted treatment of&#xD;
      neuropsychological conditions in IBD patients are crucial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify prevalence of neurological and psychological conditions associated with IBD.</measure>
    <time_frame>2021-2022</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>IBD</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HADS</intervention_name>
    <description>The HADS is a 14-item self-report questionnaire assessing levels of anxiety (seven items) and depression (seven items) over the past week. Each question is assessed on a 4-point Likert Scale: &quot;I feel tense or 'wound up'&quot; (0= not at all 3= most of the time). Consistent with recommendations by Bjelland et al cut-off of 8 for each HADS subscale will be used to differentiate normal from mild to severe distress.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients under the care of the hospital IBD outpatient service and having been diagnosed&#xD;
        with IBD, aged over 18 years&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients under the care of the hospital IBD outpatient service and having been&#xD;
             diagnosed with IBD, aged over 18 years, and able to complete the examination and&#xD;
             questionnaire.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under the age of 18.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007 May 12;369(9573):1627-40. Review.</citation>
    <PMID>17499605</PMID>
  </reference>
  <reference>
    <citation>Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005 Dec 14;11(46):7227-36. Review.</citation>
    <PMID>16437620</PMID>
  </reference>
  <reference>
    <citation>Benavente L, Mor√≠s G. Neurologic disorders associated with inflammatory bowel disease. Eur J Neurol. 2011 Jan;18(1):138-43. doi: 10.1111/j.1468-1331.2010.03095.x.</citation>
    <PMID>20500801</PMID>
  </reference>
  <reference>
    <citation>Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis. 2009 Jul;15(7):1105-18. doi: 10.1002/ibd.20873. Review.</citation>
    <PMID>19161177</PMID>
  </reference>
  <reference>
    <citation>Porcelli P, Zaka S, Centonze S, Sisto G. Psychological distress and levels of disease activity in inflammatory bowel disease. Ital J Gastroenterol. 1994 Apr;26(3):111-5.</citation>
    <PMID>8061336</PMID>
  </reference>
  <reference>
    <citation>Mittermaier C, Dejaco C, Waldhoer T, Oefferlbauer-Ernst A, Miehsler W, Beier M, Tillinger W, Gangl A, Moser G. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med. 2004 Jan-Feb;66(1):79-84.</citation>
    <PMID>14747641</PMID>
  </reference>
  <reference>
    <citation>Mardini HE, Kip KE, Wilson JW. Crohn's disease: a two-year prospective study of the association between psychological distress and disease activity. Dig Dis Sci. 2004 Mar;49(3):492-7.</citation>
    <PMID>15139504</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohamed Roshdy Abdul-Sattar</investigator_full_name>
    <investigator_title>resident doctor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

